Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA
1997

Cellular Fibronectin as a Tumor Marker

Sample size: 468 publication Evidence: moderate

Author Information

Author(s): C Haglund, S Ylatupa, P Mertaniemi, P Partanen

Primary Institution: University of Helsinki

Hypothesis

Can cellular fibronectin (cFN) levels in plasma serve as a reliable tumor marker for malignant and benign diseases?

Conclusion

The new cFN test shows promise as a tumor marker, particularly for colorectal cancer and hepatocellular carcinoma.

Supporting Evidence

  • cFN levels were higher in plasma than in serum.
  • cFN showed a sensitivity of 72% compared to 61% for alpha-fetoprotein.
  • Combination of cFN and CA 19-9 increased sensitivity to 47%.

Takeaway

This study looked at a new test that measures a substance called cellular fibronectin in the blood to help doctors find cancer. It works better for some types of cancer than others.

Methodology

Plasma and serum samples were collected from patients, and cFN levels were measured using an enzyme immunoassay.

Limitations

The study included only preoperative data and had a small number of patients in some diagnosis groups.

Participant Demographics

261 patients with malignant diseases and 207 patients with benign diseases.

Statistical Information

P-Value

0.003

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication